Regulatory Capture Comes for the Labs

Mike, Hunt, and Jason run the exhibits fast, then dig into the AI buildout math that keeps getting worse, Oracle’s brutal week, and a healthcare block anchored by Lilly’s 340B fight. As always, download the Cashflow Memo at telltales.us.The Cashflow MemoKey Takeaways* Oil has settled into a ~$70 floor with backwardation nearly gone (~$3 now vs. the $90 near-month / $75 twelve-month spread at the Iran peak), and Hunt reads the Strait of Hormuz drone tit-for-tat as an indefinite status quo gated by cargo insurance, not Iranian intent, while Northeast heat firms nat gas as power prices spike toward 15c/kWh.* The White House is clearing Anthropic’s Fable-05 (announced today) while still restricting OpenAI’s latest, a few-weeks delay the hosts dismiss as trivial and as the regulatory capture the labs originally lobbied for, with no real risk of Chinese models leapfrogging on the pause.* AI data center cost has jumped to $65–75B per gigawatt (up from $30–50B earlier this year) with memory alone now 30–40% of the build per Gavin Baker, and a structural memory shortage (Micron plus the two Koreans running low capex) plus rumored TSMC price hikes leave no one immune and make the space-based data center thesis incrementally more compelling.* Oracle logged its worst week since 2001 on a bloated risk section and dependence on OpenAI’s questionable funding, but the bull case is replacement cost: contracted capacity is worth more than Oracle spent, so the levered buildout bet holds as long as a customer exists, not necessarily OpenAI.* Eli Lilly is pressing the 340B program (now 16% of US drug sales) by demanding hospitals prove need, with Bill Cassidy legislation this week codifying the fight, while Lantheus’s FDA setback was manufacturer-controls-only (not efficacy) and dovetails with the FDA’s new PreCheck pre-clearance pilot, and Vertex’s non-opioid painkiller is climbing a flatter S-curve than hoped.Show Notes[00:00] Welcome & The Cashflow Memo Mike opens with the week’s format across energy, technology, and healthcare.[00:25] Oil at $70: Hormuz & Collapsed Backwardation Hunt on the Strait of Hormuz status quo, backwardation collapsing to ~$3, and why cargo insurance sets the real ceiling on tanker traffic.[02:26] Gas, Heat & Power Prices The Northeast heat wave firming nat gas as stressed power markets spike toward 15c/kWh.[07:23] Russia-Ukraine Stalemate & Venezuela Refinery drone strikes and fuel shortages with muted oil impact, plus Venezuela’s earthquake and the Gulf Coast’s fit for heavy crude.[11:56] Washington Clears Anthropic’s Fable-05 The White House allows Fable-05 while restricting OpenAI; regulatory capture and why the delay barely matters.[14:22] Chinese Models, Sonnet 5 & Tiered Pricing Distillation, token efficiency, and Sonnet 5 as a two-generation-old model upgraded — tiered effort as a pricing strategy.[16:04] The $75B Gigawatt & the Memory Shortage Data center cost doubling to $65–75B/GW, memory at 30–40% of the build, and a shortage that capex can’t quickly fix.[16:50] Oracle’s Worst Week Since 2001 The oversized risk section, OpenAI dependence, and the replacement-cost bull case.[18:18] Data Centers in Space Why orbit starts to pencil out when labor and time are the only knobs left to turn.[21:15] Healthcare: Pfizer, Lantheus & FDA PreCheck Pfizer’s patent-cliff cheapness, Lantheus’s manufacturer-only FDA rejection, and the FDA’s new pre-clearance pilot.[23:53] BioNTech, Moderna & Vertex’s Slow S-Curve Cash positions, pipeline burn, and a flatter-than-hoped non-opioid painkiller adoption curve.[25:07] Eli Lilly and the 340B Fight 16% of US drug sales flow through 340B; Lilly demands proof of need as Cassidy legislation codifies the battle.[27:37] Harrow Litigation & Mid-Year Predictions Preview A December 7th jury trial over a compounded product, and a predictions scorecard coming next week.Subscribe for weekly cashflow-driven investing across energy, technology, and healthcare, and grab the memo at telltales.us.Cashtags$AMZN $BNTX $GOOGL $LLY $LNTH $MRNA $MU $ORCL $PFE $TSM $VRTX This post and the information herein are intended for informational purposes only. The views expressed herein are the author’s alone and do not constitute an offer to sell, or a recommendation to purchase, or a solicitation of an offer to buy, any security, nor a recommendation for any investment product or service. While certain information contained herein has been obtained from sources believed to be reliable, neither the author nor any of his employers or their affiliates have independently verified this information, and its accuracy and completeness cannot be guaranteed. Accordingly, no representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, timeliness or completeness of this information. The author and all employers and their affiliated persons assume no liability for this information and no obligation to update the information or analysis contained herein in the future. This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit telltales.substack.com